We are live on ! Find out more
AIM icon

AIM ImmunoTech
AIM

13 hedge funds and large institutions have $4.91M invested in AIM ImmunoTech in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,274% more capital inflows, than outflows

Capital inflows: $4.33M | Capital outflows: $46.2K

12.87% more ownership

Funds ownership: 5.99% → 18.85% (+13%)

7% less funds holding

Funds holding: 14 → 13 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
13
Holders Change
-1
Holders Change %
-7.14%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$2.16M
2
Anson Funds Management
Anson Funds Management
Texas
+$2.1M
3
Panagora Asset Management
Panagora Asset Management
Massachusetts
+$21.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$21.1K
5
Renaissance Technologies
Renaissance Technologies
New York
+$14K

Top Sellers

Rank Fund Capital Flow
1
Guggenheim Capital
Guggenheim Capital
Illinois
-$10K
2
State Street
State Street
Massachusetts
-$9K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$8K
4
Citadel Advisors
Citadel Advisors
Florida
-$5K
5
Goldman Sachs
Goldman Sachs
New York
-$3K

AIM Hedge Fund Activity: Q3 2016 in Review

13 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2016, worth a combined $4.91M — up 186% from $1.72M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of AIM and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $2.16M. The largest seller was Guggenheim Capital, exiting entirely with an estimated $10K sold.

  • 13 institutional investors held AIM ImmunoTech (AIM) as of Q3 2016, down from 14 in Q2 2016.
  • Funds reported $4.91M of AIM ImmunoTech stock for Q3 2016, up 186% quarter-over-quarter.
  • 3 funds opened new AIM ImmunoTech positions in Q3 2016 and 4 closed out, a net change of -1 holder.
  • The largest AIM ImmunoTech buyer in Q3 2016 was Sabby Management, an estimated $2.16M added.
  • The largest AIM ImmunoTech seller in Q3 2016 was Guggenheim Capital, an estimated $10K sold.

Based on aggregated 13F filings for Q3 2016.